A Multicentre, Non-interventional, Observational Study to Evaluate Safety and Efficacy of NovoSeven in Patients With Glanzmann's Thrombasthenia in Japan

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

10 Jul 2017 Status changed from active, no longer recruiting to completed.
30 Nov 2016 Status changed from recruiting to active, no longer recruiting.
07 Jul 2014 According to a Novo Nordisk media release, eptacog alfa was approved by the US FDA for the perioperative management and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com